INTERVIEW: One year on - how has CardioMEMS worked out for St Jude?
This article was originally published in Clinica
Executive Summary
A few weeks ago, St. Jude Medical marked the one-year anniversary of its acquisition of CardioMEMS, developer of the CardioMEMS HF System, which became the first US FDA-approved heart failure monitor proven to significantly reduce HF hospital admissions and improve quality of life in New York Heart Association (NYHA) class III patients.
You may also be interested in...
The Sustainability Stakes Are Rising: ‘We Cannot Recycle Our Way Out Of This’
The journey to Net Zero, described as ‘the defining issue of our time,’ will get harder in the coming decade. Failure to keep up the pressure will result in more long-term health conditions, increasing deaths and higher costs. The UK NHS is a Net Zero exemplar globally, but without a systemic approach, its compliance efforts could stutter.
UK Life Sciences Cautiously Upbeat For Investment Year Ahead – BioWales 2024
Favorable UK biopharma investment trends have been reported by the BioIndustry Association, but can medtech and healthtech share in the positivity? A roundtable at the BioWales in London 2024 event framed the outlook for non-pharma players.
An Ecosystem For Medtech Funding And Innovation Support – BioWales 2024
Creo Medical and Clinithink are among the healthtech innovators who have benefited from funding and advisory support offered by the Development Bank of Wales. All three gave a take on the current funding environment at BioWales in London 2024.